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Abstract 
Next Generation Sequencing technologies have completely changed the way to study 
molecular bases underlying Rare Genetic Diseases (RGDs). Currently, sequencing of the 
exonic portion of the human genome – the exome (1%) – performed through Whole Exome 
Sequencing (WES) experiments represents the most used approach to discover molecular 
mechanisms underlying RGDs. To date, several tools have been developed to analyse and 
interpret data generated from WES. However, due to both technical and experimental 
limitations, its diagnostic rate is ~20-30%. 
In this context, we evaluated whether WES data contain information on non-coding 
sequences, focusing on microRNAs (miRNAs). Comparative analysis of capture design and 
experimental coverage allowed to disclose that in WES data reside information related to 
miRNA sequences that are efficiently captured by most exome enrichment kits. We therefore 
analysed WES of a cohort of 259 individuals, including patients affected by several genetic 
diseases and their unaffected relatives, searching for variants in miRNAs and performing 
functional annotation. Sanger sequence validation confirms the reliable call of variants 
mapping in miRNA sequences. 
To date, no dedicated tool is available to properly retrieve and analyse miRNAs from 
WES and WGS data. We therefore developed a tool, “AnnomiR”, that allows to systematically 
analyse miRNA variants and miRNAs, providing functional annotation retrieved from 
several databases. This tool can be integrated in a standard workflow of analysis for WES and 
WGS data. 
WES data contain a great amount of information that is generally discarded by 
commonly used workflow of analysis and that should be considered, as it could help in the 
comprehension of molecular mechanisms underlying RGDs. In this context, systematic study 
of miRNAs could help elucidating their role as disease-causative and phenotypic modifiers in 
a wide spectrum of human diseases, allowing to achieve a better characterisation of variability 
of the human genome related to these non-coding sequences. 
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1. Introduction 
1.1 Rare Genetic Diseases’ molecular bases identification: the advent 
of Next Generation Sequencing 
Rare diseases are defined as diseases that affect fewer than 200,000 people in US1 or 
less than 1 in 2,000 in Europe2. Therefore, these diseases, though individually rare, are 
collectively common. Rare diseases have been estimated to be 7,000, ~80% of which has genetic 
causes3, prevalently, alterations of single genes4. Molecular bases of these Rare Genetic 
Diseases (RGDs), also called monogenic or Mendelian diseases, have been extensively 
studied, leading to the determination of more than 3,500 disease-gene associations5.  
First successes in the identification of disease-gene associations were obtained through 
a combination of linkage analysis, positional cloning and sequencing of candidate genes6,7.  
Linkage analysis is based on the observation that genes physically close on a chromosome co-
segregate during meiosis8. In this approach, the sequencing of several affected individuals 
and controls from a set of families (or from the same one), using a group of DNA 
polymorphisms, allows to calculate the probability that two loci are genetically linked6,8. The 
comparison of linked regions obtained, with information on status of affected members is then 
useful to discriminate between regions presumably containing disease-causative mutations 
and regions not relevant in the physiopathology of the disease. Linkage analysis often 
represents the first step for positional cloning9. Starting from a previously identified candidate 
region, positional cloning is used to narrow this genomic region, with the intent to identify 
gene (or genes) in which disease-causative mutations could rely. Combined approach of 
linkage analysis followed by positional cloning allowed to identify several disease-gene 
associations, as in the case of CFTR for Cystic Fibrosis10 (MIM: 219700) and HTT for 
Huntington disease11 (MIM: 143100). While linkage analysis and positional cloning do not 
require any functional information on genes associated with RGDs, candidate-genes approach 
is based on Sanger sequencing of genes that seem to be involved in the disease investigated. 
These genes can be selected for several reasons: because they resemble genes associated with 
similar diseases, because their protein products seem to be correlated with the 
pathophysiology of the disease, or because they are located in a relevant region previously 
identified with other strategies (e.g. linkage analysis)7. Through candidate-gene approach 
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many disease-causative mutations were discovered as those in p53 associated with Li-
Fraumeni syndrome12 (MIM: 151623).   
However, several factors limit the power of these traditional methods as the 
availability of a small number of cases, the lack of a priori biological information, the reduced 
penetrance of a mutation, and locus heterogeneity7,13. 
Improvements in DNA sequencing, achieved through the introduction of Next 
Generation Sequencing (NGS) technologies in 2009, have allowed to overcome these 
limitations. Sequencing a genomic region of interest with a single-nucleotide resolution in a 
rapid and cost-effective way, NGS substantially changed the way to study RGDs, accelerating 
the pace of discovery of molecular bases underlying human diseases. From its first application 
in medical genetics - that led to the identification of disease-causative mutations in DHODH 
gene in patients affected by Miller syndrome14 (MIM: 263750) – NGS has allowed to elucidate 
many other disease-gene associations4,15. 
NGS technologies used to sequence human DNA can sequence a specific panel of 
genes (targeted sequencing - TS), the coding portion of the human genome – the exome – 
(Whole Exome Sequencing) or the entire genome (Whole Genome Sequencing). NGS 
experiments produce a large amount of data, demanding several bioinformatics tools to detect 
and interpret variations identified. Therefore, one limiting factor in the application of these 
methods is represented by the analysis and the interpretation of the data, rather than their 
production. As the amount and the kind of variations identified strictly depend on the 
sequencing approach, all NGS strategies present advantages and limitations in terms of costs 
and data analysis. Consequently, the choice of the appropriate method is generally guided by 
a priori knowledge of molecular defects underlying the disease investigated (e.g. known 
disease-gene associations) and by hypothesis on kind of disease-causative mutations (e.g. 
sequence variations rather than chromosomal rearrangements). 
TS is used to sequence either a panel of genes known (or predicted) to be associated 
with the investigated disease, or the entire set of genes known to be mutated in Mendelian 
diseases – the Mendeliome – composed by ~5000 genes16. This approach has the great 
advantage of identifying a small number of variations strictly related to the genes of interest, 
and of facilitating their interpretation. For these reasons, TS has been revealed a powerful tool 
at identifying disease-causative mutations in Mendelian cohorts17. Limitations of TS reside in 
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its partial ability to detect clinically relevant sequence variants, especially Copy Number 
Variants (CNVs); moreover, due to the high increase of disease-gene associations discoveries, 
gene panels require continuous updates. Therefore, TS may be inconclusive in cases in which 
disease-causative mutations are not identified, often requiring additional tests16.  
WES experiments perform sequencing of the coding portion of all known genes (1% 
of the human genome), allowing to overcome some of TS limitations. Conversely from TS, 
WES may be used not only to detect new disease-causative mutations but even to discover 
new disease-gene associations. Due to low costs and to the plenty of bioinformatics tools 
available for data analysis, WES has been widely used in medical genetics, leading to the 
comprehension of molecular bases of several RGDs13. However, several limitations, as the 
inability to assess non-coding variations, narrow WES successful rate, that is attested to be 
~20-30%16,18.  
WGS has the advantage of sequencing the entire genome, allowing to detect all 
sequence and structural variations. Thus, compared to WES, WGS has a greater successful 
rate15,16 even if its use is limited by the high costs and the lack of tools and abilities to deeply 
analyse and interpret data obtained. With the passing of these limitations, WGS will be widely 
used in the study of RGDs, leading to a better elucidation of molecular mechanisms 
underlying human diseases4.  
1.2 Whole Exome Sequencing  
Among NGS technologies, WES is currently the most used approach in the study of 
molecular bases of RGDs4,15. Indeed, due to the observation that 85% of disease-causing 
mutations reside within protein-coding genes19, and due to the accessible costs, WES has been 
largely applied in medical genetics, leading to the conversion of this approach from a research 
tool to a diagnostic one4,15.  
1.2.1 Whole Exome Sequencing experimental procedure 
Exome experiments can be performed following different protocols, all requiring 
fundamental steps of exome capture and sequencing13,20.  
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DNA fragmentation represents the starting point of exome capture and it can be 
performed through chemical, physical or enzymatic methods (Figure 1). Fragments obtained 
are ligated to adaptors, to generate a library. Next, the library obtained is enriched for 
sequences corresponding to exons. Among strategies available to capture protein-coding 
sequences21, the capture by hybridization approach in the aqueous-phase is the most used. In 
this case, the selection of exonic sequences occurs through the hybridization of the library with 
an exome enrichment kit constituted by DNA or RNA biotinylated baits complementary to 
sequences of interest. Recovery of hybridized fragments (corresponding to exonic sequences) 
is then performed through biotin-streptavidin-based pulldown13.  
Fragments recovered are successively amplified following technology used by the 
sequencer chose. Among amplification strategies20, the most diffuse is the one used by 
Illumina platforms, represented by a solid-state amplification, specifically, a bridge-
amplification (Figure 2). In this technique, DNA captured fragments are hybridized to a solid 
Figure 1. Library construction for WES experiment.  Genomic DNA is fragmented through different 
systems to create a library. Fragments obtained are then ligated to adaptors (shown in yellow and light 
purple). After adaptors ligation, fragments are enriched for exonic sequences (dark blue) using an 
exome enrichment capture system constituted by RNA or DNA probes (orange sequences) that are 
biotinylated (red dots on orange sequences). Fragments hybridized, corresponding to exonic sequences, 
are then recovered through a biotin-streptavidin based pulldown, while the ones not ligated are 
washed away. Figure adapted13. 
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surface in which forward and reverse primers, complementary to the adaptors on the 
fragments, are found. Each single-stranded DNA fragment binds to one of the primers and a 
polymerase creates the complementary sequence. Once that double-strand DNA molecule has 
been generated, it is denatured, and the two single-stranded DNA fragments obtained fold 
over, binding the nearby primers and encountering a new process of sequencing. This process 
is repeated many times, generating a cluster containing millions of copies of the starting DNA 
fragment.  
Once that DNA fragments have been amplified, they are sequenced through short-
read sequencing approaches, based on sequencing by ligation (SBL) or sequencing by 
synthesis (SBS)20. In SBL approaches, a probe sequence is labelled with a fluorophore and, 
when the probe hybridizes to a DNA fragment, it releases the fluorophore, allowing to 
identify the probe complementary to the sequence, through the emission spectrum generated. 
In SBS approaches, when a nucleotide is incorporated during extension of a DNA fragment, 
it releases a signal such as a fluorophore or a change in ionic concentration, that allows to 
identify the nucleotide20.  
Figure 2. Solid-phase bridge amplification. In Illumina sequencers, library amplification is performed 
in a solid-phase. The solid surface used shows forward and reverse primers (yellow and light purple 
fragments) complementary to the adaptors ligated to the DNA fragments during library generation 
(Figure 1). DNA single-stranded fragments obtained from previous phase, are hybridized to the solid 
surface. Each DNA fragment binds to one of the primers on the solid surface and a polymerase is used 
to create the complementary sequence (figure on the left). Double-strand DNA molecules synthetized 
are denatured, and the two single-stranded DNA molecules resulting, fold over (figure on the right), 
binding nearby primers and being sequenced again. This process is also called cluster generation since 
it generates a cluster of identical fragments starting from the same DNA molecule. Cluster generated 
are then sequenced through a short-read sequencing process based on sequencing by ligation or 
sequencing by synthesis approach.  Figure adapted20. 
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1.2.1.1 Comparison of sequencing platforms and exome enrichment 
capture systems 
Among short-reads platforms, SBL technique is mostly used by SOLiD (Thermo Fisher 
Scientific) and Complete Genomics (BGI) systems20. These platforms can generate reads very 
different in length, ranging from 75 bp for SOLiD to 28-100 bp for Complete Genomics20. 
Although these systems show high accuracy in base identification (~99,99%) as each base is 
probed multiple times, they present several limitations, as low sensitivity and specificity, since 
true variants are missed while few false variants are called20. The SBS technique is used by 
Illumina sequencers which generate reads of length up to 300 bp20. Although these platforms 
show a lower accuracy compared to SOLiD and Complete Genomics systems (> 99.5%)20, they 
also show a higher sensitivity (even if false-positive rate is around 2.5%)20. Therefore, 
providing a wide range of sequencers20, Illumina NGS platforms are currently the most used 
for short-reads sequencing. 
To perform exome capture, several exome enrichment systems have been developed. 
Most used kits provided by Roche NimbleGen, Agilent Technologies and Illumina, show 
several differences in terms of target size and design. The dimensions of kits commercially 
available span from ~37Mb of Nextera Rapid Capture Exome (Illumina) to ~67Mb of 
SureSelect Clinical Research Exome V2 (Agilent Technologies). Differences observed in target 
size are mostly due to target design. Indeed, exome enrichment capture systems are designed 
considering gene sequences contained in several databases as RefSeq (NCBI Reference 
Sequence Database)22, GENCODE23 and CCDS (Consensus CDS)24. In addition to capture 
exonic regions, exome enrichment kits can also contain probes targeting protein non-coding 
sequences, as microRNAs (miRNAs). In this case, reference database used is represented by 
miRBase (the microRNA database)25 which contains information on all miRNA sequences 
identified in more than 200 species. Moreover, exome enrichment kits may be available in 
expanded versions, with probes for sequences outside coding exons. This is the case of 
SureSelect Human All Exon V6+UTR (89Mb, Agilent Technologies) which target regions 
include 5’ and 3’ UTR regions, and of SeqCap EZ MedExome (Roche NimbleGen) that, 
combined with SeqCap EZ Mitochondrial Genome Design (Roche NimbleGen), allows to 
sequence the entire mitochondrial DNA. 
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1.2.2 Whole Exome Sequencing bioinformatics processing  
WES experiments produce a large amount of data that can vary substantially, 
according to the experimental design (e.g. due to the exome enrichment kit used). 
Fundamental steps in the processing of WES data require the alignment of the reads to the 
reference genome, the identification of variants present in the WES analysed (i.e. variant 
calling) and the functional annotation of variants and genes identified (Figure 3). 
A WES experiment generally produces from tens to hundreds of millions of reads 
stored in FASTQ files. Prior to the alignment step, reads are treated to remove the adaptors 
used during sequencing experiment, to obtain reads containing only sample DNA sequences. 
For adapter trimming, several tools can be used, as TrimGalore!II and Trimmomatic26. File 
produced from this pre-processing step is still a FASTQ file. Trimmed reads are then aligned 
to the reference genome through tools as Burrows-Wheeler Aligner (BWA)27 and NovoAlignIII.  
Currently, the assembly hg38/GRCh38 represents the most recent update of the human 
reference genome, even if analyses can be also performed using previous genome version, 
Figure 3. Genome Analysis Toolkit (GATK) pipeline for germline variants discovery. According to 
GATK pipeline, widely used for germline short variant discovery, raw data produced are aligned to 
reference genome. Raw mapped reads are analysed to identify and mark duplicated reads. Base quality 
scores are recalibrated, and germline variants are identified applying “HaplotypeCaller” algorithm. If 
multiple samples are available (e.g. in case of a trios), only one variant calling step (joining the three 
samples) should be performed. After variant calling step, raw single nucleotide variants and small 
insertions and deletions identified should be filtered, according to quality criteria. At this step, 
genotypes can be refined, and variants can be annotated. Figure reprinted from GATKI 
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hg19/GRCh37. Indeed, for hg19/GRCh37 assembly, a plenty of tools has been developed 
during past years, while tools available for the most recent version of the human genome are, 
in large part, still under development. After the alignment step, the mark of PCR duplicates 
is required, since WES experiments produce a lot of duplicated reads, due to the clonal 
amplification, that are uninformative for variants detection. Therefore, through tools as 
MarkDuplicates by PicardIV or markdup by SAMtools28, PCR duplicates are flagged and easily 
discarded. Next step is represented by base quality recalibration (Base Quality Score 
Recalibration - BQSR) generally performed through Genome Analysis Toolkit (GATK)29. 
BQSR estimates systematic errors made by the sequencer during base calling and, 
consequently, it adjusts overall base quality values. As variant calling algorithms highly rely 
on quality values assigned to each base call, BQSR is a fundamental step to get more accurate 
base qualities, which in turn improves the accuracy of variant calling. The file obtained from 
the steps of alignment to the reference genome, mark of PCR duplicates and BQSR is a BAM 
(Binary Alignment Map) file which dimensions can vary from 6 to 13 Gb16. Parameters as 
coverage, depth and unique mapped reads can be used, at this level, to evaluate the quality 
of data (Figure 4). Considering a genomic region, coverage refers to the extension of the 
effective capture of the region (expressed as a percentage), while depth is related to the 
number of reads that supports each base in the region (and it is expressed as a number). 
Unique mapped reads refer to the reads that, depleted from PCR duplicates, can be used to 
call variants. 
Variant calling is the process in which WES data are analysed to identify variants.  
GATK HaplotypeCaller29 is the most used tool to perform germline variant calling, identifying 
both single-nucleotide variants (SNVs) and small insertions and deletions (indels). Variants 
identified are reported in a VCF (Variant Call Format) file and they can be filtered, according 
to quality criteria, to retain only reliable ones. 
Finally, variants and genes in which variants localise are annotated to evaluate their 
potential biological role. Functional annotations on variants may regard their effect on 
transcripts, their frequencies in population databases and information on already known 
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disease-causative mutations. Functional annotation on genes may involve gene function, gene 
pathways, gene ontology, phenotypes caused by homolog genes, and already known disease-
gene associations. 
To annotate variants effect on transcripts, several tools can be used as ANNOVAR30, 
SnpEff31, and VEP (Variant Effect Predictor)32. Using as a reference database a set of 
transcripts, as RefSeq22, GENCODE23, or Ensembl33, these tools identify variants localisation 
in transcripts, evaluating possible functional consequences (e.g. whether variants alter an 
exonic sequence).  Variants frequencies across several populations can be retrieved from 
databases as dbSNP (Database of Single Nucleotide Polymorphisms)34, 1000 Genome35 or the 
most recent gnomAD (genome Aggregation Database)36 comprehensive of more than 120,000 
WES and 15,000 WGS data. Other information on variants can be added considering their 
conservation across genomes, using software as phyloP37 and GERP++38. Information related 
to already known disease-causative mutations can be added through databases as HGMD 
(The Human Gene Mutation Database)39 and ClinVar40. Databases containing population 
frequencies, conservation scores and known disease-causative mutations (and others 
Figure 4. Coverage, depth and unique mapped reads. After the first step of pre-processing, BAM files 
can be evaluated considering parameters of coverage, depth and unique mapped reads. Coverage 
parameter expresses in percentage the extension of a region of interest covered by reads aligned. Depth 
parameter (also called depth of coverage) is calculated at a nucleotide level and refers to the number of 
reads that support a specific call. Coverage and depth can be combined to obtain summary statistics 
indicating the percentage of a region of interest covered at a defined depth (e.g. a region of interest can 
be covered at 90% with a depth of 20X, meaning that at least 20 reads cover the 90% of the region 
investigated). Finally, unique mapped reads parameter indicates reads, depleted from PCR duplicates 
(shown in orange), that should be considered to perform variant calling. Unique mapped reads 
parameter can be evaluated both as a number and as a percentage. Since duplicated reads introduce a 
bias in the evaluation of coverage of a region of interest (as they increase the number of reads mapping 
in the region), coverage and depth parameters should be calculated on unique mapped reads. 
14 
 
information, Table 1) can be separately added or can be comprehensively annotated using 
metadatabases, as dbNSFP48, which contain data for both variants and genes functional 
annotation.  
Information on gene function can be retrieved from databases as UniProt49. To 
annotate gene pathways, single resources as KEGG (Kyoto Encyclopedia of Genes and 
Genomes)50, or systems integrating databases, as ConsensusPathDB51, can be used. Genes may 
also be analysed using information coming from databases that classify them relying on 
biological, molecular and cellular features, as GO (Gene Ontology)52. To analyse possible 
involvement of genes in the disease investigated, information may also come from homolog 
genes functions and phenotypes-homolog genes associations. To this aim, information 
contained in databases regarding mouse and zebrafish, as MGI (Mouse Genome Informatics)53 
and ZFIN (The Zebrafish Information Network)54 respectively, can be used. Finally, 
information on genes already associated with diseases may be obtained from OMIM (Online 
Mendelian Inheritance in Man)55 or HGMD39 databases. 
Table 1. Functional annotation on variants and genes that can be integrated in analysis of WES data. 
Tool Annotation on Purpose Reference
ESP6500
(Exome Sequenincg Project v. 6500)
Variants Reports population-specific variants frequencies Exome Variant Server
41
ExAC
(Exome Aggregation Consortium)
Variants Reports population-specific variants frequencies Lek et al., 2016
36
PhastCons Variants Identifies conserved sites scoring each substitution Siepel et al., 2005
42
InterPro Variants
Provides information on protein domain in which 
the variant locates
Finn et al., 2017
43
BioCarta Genes Provides information on gene pathways Nishimura, 2001
44
RVIS Genes
Gives a score to genes in terms of whether they 
have more or less common functional genetic 
variations
Petrovski et al., 2013
45
Expression Atlas Genes
Provides information on genes and proteins 
expression across species and biological conditions
Petryszak et al., 2016
46
HI Genes Estimates probability of genes haploinsufficiency Huang et al., 2010
47
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1.2.3 Whole Exome Sequencing data analysis 
WES data analysis can be performed considering either the whole gene set or using an 
in silico panel of genes16, which can be firstly analysed to facilitate variants interpretation, and 
that can be subsequently expanded. Furthermore, as 85% of disease-causative mutations in 
Mendelian diseases resides in protein coding-regions19, pipelines used to analyse WES data 
generally analyse only SNVs and indels that fall in these regions. WES data analysis focuses 
on non-synonymous, non-sense, frameshift and on splice donor and acceptor variants. Then, 
to identify possible disease-causative mutations, several filters can be applied, based on 
biological observations and functional annotations. 
Biological information may come from phenotype observed, may regard molecular 
analyses previously assessed on the patient (e.g. linkage analysis, SNP array, CGH array), 
may come from his familiar history (e.g. pedigree information) or from other non-related 
affected patients. 
Functional annotations can be used to filter variants and genes. The most used filter 
relies on variants frequency. Indeed, as disease-causative mutations would be rare and 
therefore likely to be previously unidentified, population databases information is used to 
remove annotated variants with high frequency. 
Furthermore, several strategies may be used to prioritise variants and genes, to 
identify those potentially related to the disease investigated. Among tools that predict 
variants potential deleterious effect, there are PolyPhen-2 (Polymorphism Phenotyping v2)56 
and SIFT (Sorting Intolerant From Tolerant)57, which score only non-synonymous variants, 
and systems as CADD (Combined Annotation Dependent Depletion)58 and DANN59 that 
through a machine-learning system approach, trained on comparative genomics data, allow 
to assess the potentially damaging effect of all SNVs and indels. Furthermore, other tools can 
be used to predict variants interfering with splicing, as dbscSNV60 or SPIDEX61 which are 
respectively based on data coming from several databases and from RNA sequencing (RNA-
seq) experiments. 
For genes prioritisation, several strategies can be used, mostly relying on the 
identification of similarities between genes investigated and already known phenotype-gene 
associations. Among these tools, there are GeneDistiller62 and the most recent Phenolyzer63 
which allows to better define phenotype investigated, considering phenotypic standardised 
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terms (taken from HPO – The Human Phenotype Ontology)64, and therefore to discover more 
accurate associations of genes with similar phenotypes.   
To interpret the clinical relevance of variants prioritised, tools as InterVar65 or Sherloc66 
can be used.  Applying ACMG-AMP (American College of Medical Genetics and Genomics - 
Association for Molecular Pathology) guidelines67, these tools classify variants, allowing to 
reveal those definable as pathogenic according to standardised criteria. Moreover, as one of 
the big issues related to WES data analysis concerns secondary findings, these tools allow to 
assign a clinical significance also to variants that are not necessarily correlated with the disease 
investigated, improving patient management.   
1.3 Limitations and potentialities of Whole Exome Sequencing 
WES successful rate has been estimated to be ~20-30%16,18, despite the number of tools 
available to analyse data and interpret variants. This can be due to a combination of biological, 
technical and analytical reasons that can limit the power of new disease-gene discovery (Table 
2).  
Although WES presents fundamental limitations, it can also provide a meaningful 
amount of information, usually discarded by commonly used workflow analyses68, and that 
should be considered as it can have a relevant biological role in the phenotype investigated.  
Indeed, a recent study published by Bergant and colleagues showed that an extended exome 
analysis improved their diagnostic rate of ~4% in a cohort of more than 1000 cases69.  
Several tools have been developed to analyse from WES data information related to 
genome, as for Copy Number Variants (CNVs) and Regions of Homozygosity (ROHs), and 
for synonymous and non-coding variants. Thus, even if molecular cytogenetic methods (as 
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CGH and SNP array) and WGS experiments can be more accurate in the analysis of these 
genomic elements, they can also be analysed starting from WES data. 
1.4 MicroRNAs: biogenesis, function, and involvement in Rare Genetic 
Diseases 
MicroRNAs (miRNAs), which have been shown to play an important role in RGDs70, 
are small non-coding RNAs of ~22 nucleotides, widely expressed in all human tissues, that 
interfere with gene translation by targeting 3’ untranslated regions (UTRs) of messenger 
RNAs (mRNAs)71,72. MiRNAs are mainly transcribed by RNA polymerase II, from long non-
coding RNAs, intronic regions and, to a lesser extent, from exonic regions72,73 (Figure 5). 
Several miRNA loci can be found near each other, therefore constituting a polycistronic 
transcription unit72,73. Transcription of miRNA genes generate primary miRNA (pri-miRNAs) 
transcripts that are further processed in the nucleus. Drosha and DGCR8 cleave the pri-
miRNA leading to the formation of a precursor miRNA (pre-miRNA), ~70 bp long, which 
shows a 2-nucleotide overhang at 3’ end. Exportin 5 recognises the pre-miRNA and exports it 
to the cytoplasm. Here another protein, Dicer, which acts as a ‘molecular ruler’, cleaves the 
Table 2. Factors contributing to bottlenecks in the identification of new disease-causative mutations 
and new disease-gene associations. Table adapted4. 
Level of analysis Possible issues
Clinical data
•non-specific clinical presentations (e.g., developmental delay and hypotonia) 
•ultra-rare and unrecognized genetic diseases
•lack of ontology encompassing the complete spectrum of human phenotypes
•insufficient utilization of ontologies or 3D facial-gestalt analysis in phenotyping
•inconsistent multidisciplinary approaches to patient evaluation
•inability to account for and compare age-specific disease presentations
Genomic data
•technical limitations of WES (e.g., copy-number variants and structural variation are not 
captured well)
•lack of standardized technical and informatics approaches
•incompleteness of population-specific control datasets
Data discovery and sharing
•lack of a widely adopted data-sharing framework
•lack of common data-sharing standards
•lack of a systematic way to record data-use conditions
•lack of a privacy-preserving linkage system for each research participant
Genetic evidence
•siloed datasets
•lack of and use of data-sharing infrastructure
Functional evidence
•lack of standardized and moderate-throughput analyses of variant impact
•lack of biological insight into the function of most human genes
Novel disease mechanisms
•other mechanisms including tissue-specific mosaicism, methylation, and di- or oligogenic 
inheritance
18 
 
pre-miRNA generating a mature-miRNA duplex (composed of two mature miRNAs), with 
another typical 2-nucleotide 3’overhang72. One of the two mature miRNAs, the ‘guide strand’, 
is loaded into one of four AGO proteins (AGO 1-4) to form an effector complex called RNA-
induced silencing complex (RISC)73, while the other mature miRNA, the ‘passenger strand’, is 
discarded. Loading preference is given to the less stably 5’ end72. Along with canonical mature 
miRNAs, there can be produced multiple isoforms, isomirs, that originate from pri-miRNA 
modifications, due to an RNA A-to-I editing process, or from different cleavages performed 
by Drosha and Dicer71,72. 
Figure 5. MicroRNA biogenesis. Figure adapted72 
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The RISC complex can act binding target sites for miRNAs which are generally located 
in 3’ UTRs of mRNAs and are highly complementary to miRNAs seed regions. Seed region of 
a miRNA is generally defined as the region spanning from second to eighth nucleotide at 
mature 5’ end. Moreover, miRNAs can present specific sequences motifs based on AGO 
proteins on which they are loaded. This is the case of miRNAs loaded into an AGO2 protein 
which tend to show an A or a U at 5’-terminal-nucleotide, since AGO2 protein prefers one of 
these two nucleotides as first base. Through seed region, mature miRNAs can bind one or 
more mRNAs and mediate gene silencing through translation repression and mRNA decay72. 
Although these two modes seem to be interconnected, it has been observed that from 66 to 
90% of gene silencing events occur through mRNA decay72. 
Since one miRNA can target more genes and more miRNAs can interact with the same 
gene, deregulation of miRNAs function has been associated with several human diseases, 
particularly cancer74, but even RGDs70. MiRNA variants associated with RGDs have been 
found in genes responsible for miRNA biogenesis, in miRNA target sites and in miRNA 
sequences70. 
Since multiple enzymes and cofactors participate in the biogenesis of miRNAs (e.g. 
Drosha and Dicer), pathogenic variants in these genes generally result in the reduced 
efficiency of miRNA processing, which can lead to human diseases70. Several disease-
causative variants have been found in these genes, as in the case of DICER1 whose 
heterozygous germline variants have been associated with Familial Pleuropulmonary 
Blastoma (PPB, MIM: 601200)75. 
Disease-causative variants in miRNA binding sites may function as regulatory 
elements through modifying miRNA binding affinity and/or specificity, leading to a 
deregulation of expression of target genes. Among variants identified in 3’ UTR binding sites, 
a variant in 3’UTR of gene SLITRK1 was found in patients affected by Tourette syndrome 
(MIM: 137580)76. 
Pathogenic variants in mature miRNAs can alter miRNA processing and miRNA 
targeting, leading to the recognition of many novel and aberrant direct targets. Few disease-
causing variants in miRNA sequences have been associated to Mendelian diseases so far, 
specifically in miR-96, miR-204 and miR-184.  
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In 2009 Mencía and colleagues analysed a Spanish family affected by non-syndromic 
progressive hearing loss (MIM: 613074), revealing the presence of two disease-causative 
variants in seed region of miR-9677. These variants significantly alter both miRNA biogenesis, 
leading to a reduced expression of mature miRNA, and miRNA targeting, bringing to an 
overexpression of several predicted miRNA target genes expressed in the inner ear (as AQP5, 
ODF2, MYRIP and RYK). The variants identified in miR-96 were therefore recognised as 
disease-causative for non-syndromic progressive hearing loss77. Moreover, another variant in 
miR-96 precursor sequence was found associated with the same phenotype, impairing both 
mature miRNAs processing and expression78. 
Another pathogenic variant in the seed region of a mature miRNA was found in miR-
204 by Conte and colleagues in 2015 in patients showing retinal dystrophy associated with 
ocular coloboma79. Studying a five-generation family, a pathogenic variant in the seed region 
of miR-204 was identified. This variant alters miRNA targeting, through the loss of canonical 
gene targets and the creation of new ones. These alterations are responsible for an increase of 
retinal cell apoptosis, that lead to a reduced number of both cones and rods photoreceptor 
cells, causing a phenotype consistent with the one observed in the family79. 
In 2011, Hughes and colleagues, identified a disease-causative variant in miR-184 
responsible for keratoconus and early-onset anterior polar cataracts in a large Irish family80.  
The mutant miR-184 fails to compete with miR-205 for overlapping target sites on the 3’ UTRs 
of INPPL1 and ITGB4 genes, leading to their dysregulation. Although these target genes and 
miR-205 are expressed widely, miR-184 is highly expressed only in cornea and lens. Therefore, 
phenotype observed, due to miR-184 pathogenic variant, is restricted to these tissues. The 
same variant was also found in patients affected by EDICT syndrome (MIM: 614303) showing 
differences in keratoconus phenotype81 compared with the family reported by Hughes and 
colleagues, thus supporting the hypothesis that other genetic modifiers can explain different 
corneal phenotype in these two families. Moreover, two new pathogenic variants in miR-184 
were found in patients affected by isolated keratoconus. These variants reside in precursor 
sequence of miRNA and interfere with efficiency of processing82. 
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1.5 Methods used to study microRNA sequences and expression 
Since miRNA dysregulation may have substantial effects on gene silencing, miRNAs 
have been extensively studied, firstly focusing on their expression profiles. Studying miRNA 
expression variability can be very informative, elucidating biological processes in which 
miRNAs play a crucial role, as organismal development and establishment and maintenance 
of tissue differentiation83.  
Three major approaches are currently used to study miRNAs profiling: hybridization-
based methods (e.g. DNA microarrays), quantitative reverse transcription PCR (qRT-PCR) 
and NGS approaches (RNA-seq)83. 
Hybridization-based methods, as microarrays, were among the first methods used to 
study simultaneously several miRNAs. These experiments are based on the reverse 
transcription of miRNAs, on their labelling (e.g. by fluorescence), and their subsequent 
hybridization on an array in which there are DNA complementary probes. Even if these 
systems have really low-costs, they do not allow to perform absolute quantification of 
miRNAs considered, as well as they cannot identify novel miRNAs83.  
Methods as qRT-PCR are based on the reverse transcription of miRNAs to cDNAs. 
Once obtained cDNAs, there are amplified through a qPCR with real-time monitoring of 
reaction product accumulation. Although these systems allow to obtain an absolute 
quantification of miRNAs amplified, these techniques do not allow to discover new 
miRNAs83. 
NGS experiments have allowed to completely change the way in which miRNA 
profiling is performed. Indeed, RNA-seq based on NGS technologies allows to simultaneously 
study a plenty of miRNAs. The great advantage of this technique, compared with microarrays 
and qRT-PCR, resides in its ability to investigate both miRNA expression profiles and their 
sequences, not only analysing already known miRNA sequences, but even investigating those 
completely new83. 
Due to this great advantage, RNA-seq has quickly become the most diffuse approach 
to analyse both miRNA sequences and their expression profiles in a sample.  
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1.5.1 MicroRNAs and Whole Exome Sequencing 
Even if miRNA expression profiles can be only detected through the aforementioned 
methods, miRNA sequences can also be recovered from WES data. Indeed, exome enrichment 
capture systems may enclose probes to capture also miRNA sequences.  
One of the evidences of the presence of miRNA information in WES data comes from 
the work of Carbonell and colleagues84. To study miRNA variability in the human genome, 
they collected 1,152 healthy individuals. For 60 of them a WES experiment was performed 
using SeqCap EZ Exome (Roche NimbleGen), while for the remaining 1,092, data were 
downloaded from 1000 Genome Project84. Since the exome enrichment kit chose has been 
designed considering 720 miRNAs (taken from miRBase v13), they analysed all the samples 
considering variants localised in these miRNAs84. 
WES also allowed to discover one of the disease-causative variants in miRNAs 
associated with RGDs, specifically in the case of miR-20479. Focusing on a candidate region 
evidenced by linkage analysis, the authors analysed WES data, discovering the variant 
reported79. 
Taken together these evidences suggest that information regarding miRNAs may 
reside in WES. However, currently, there are not dedicated tools to retrieve miRNA related 
information from WES data. 
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2. Aim of the thesis 
The aim of this thesis was to investigate the presence of information related to miRNA 
sequences in WES data. To this purpose, we evaluated the ability of the most used exome 
enrichment capture systems commercially available to effectively capture miRNA sequences. 
Then, we developed a dedicated tool to retrieve, analyse and functionally annotate variants 
in miRNAs. To test our tool, we analysed WES data of a cohort of 259 individuals including 
patients affected by different genetic diseases. 
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3. Material and Methods 
3.1 Whole Exome Sequencing and microRNAs: capture evaluation 
We investigated which amount of miRNA-related information could be found in WES 
data. To this aim, we evaluated both theoretical and experimental coverage relative to miRNA 
sequences using several exome enrichment capture systems commercially available: SeqCap 
EZ Human Exome Library v3.0 (Roche NimbleGen), SeqCap EZ MedExome (Roche 
NimbleGen), Nextera Rapid Capture Exome (Illumina), SureSelect Human All Exon V4 
(Agilent Technologies), SureSelect Clinical Research Exome (Agilent Technologies), 
SureSelect Clinical Research Exome V2 (Agilent Technologies), SureSelect Human All Exon 
V6 (Agilent Technologies).  
Most exome capture systems are designed on hg19/GRCh37 assembly (except for 
SeqCap EZ MedExome, designed on hg38/GRCh38). Therefore, to evaluate miRNAs coverage, 
we considered miRNA “primary transcript” sequences, as reported in miRBase v2025 (version 
designed on assembly hg19/GRCh37). To perform coverage analyses we used bedtools 
package (version 2.26), composed by a series of utilities that allow to perform several 
genomics analyses85. 
3.1.1 Theoretical coverage 
As a first step, we evaluated whether exome enrichment capture systems contain 
probes to specifically capture miRNA sequences. To this aim, we compared genomics 
coordinates of target regions for each kit considered with miRNA “primary transcripts” 
defined in miRBase v2025. For SeqCap EZ MedExome we considered coordinates of capture 
regions based on assembly hg19/GRCh37 as furnished by Roche NimbleGen. We therefore 
evaluated miRNA sequences overlapping at least at 50% with target regions, using bedtools 
“intersect” tool (version 2.26)85. We chose this overlapping threshold since miRNA “primary 
transcript” sequences are ~80bp long while target regions are generally larger and, 
consequently, we expected that overlapping target regions would be able to capture miRNA 
full sequences. Histogram showing theoretical coverage of miRNA sequences was generated 
using “ggplot2”86, a R library. 
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3.1.2 Experimental coverage 
Then we evaluated whether exome baits would be effectively able to capture miRNA 
sequences. To this purpose, we selected 14 WES data captured through different exome 
enrichment capture systems (Table 3).  
To perform coverage analysis, we considered WES BAM files. Briefly, raw exome data 
were aligned to the reference genome, assembly hg19/GRCh37, using BWA-MEM algorithm87. 
PCR duplicates were then removed using MarkDuplicates by PicardIV. In some cases, Base 
Table 3. WES cases considered for evaluation of miRNA sequences coverage in WES data. Table 
reports pre-processing steps performed to generate BAM files analysed, along with algorithms used 
and respective versions. BQSR stands for Base Quality Score Recalibration. 
Case Exome enrichment capture system Alignment to reference genome Removal of PCR duplicates BQSR
1
SeqCap EZ Human Exome Library v3.0
(Roche NimbleGen)
BWA-MEM, 
version 0.7.10
Picard MarkDuplicates,
version 1.119
Not performed before 
generating final BAM
2
SeqCap EZ Human Exome Library v3.0
(Roche NimbleGen)
BWA-MEM, 
version 0.7.10
Picard MarkDuplicates,
version 1.119
Not performed before 
generating final BAM
3
SeqCap EZ MedExome 
(Roche NimbleGen)
BWA-MEM,
version 0.7.12
Picard MarkDuplicates,
version 2.3.0
Not performed before 
generating final BAM
4
SeqCap EZ MedExome 
(Roche NimbleGen)
BWA-MEM, 
version 0.7.10
Picard MarkDuplicates,
version 1.119
Not performed before 
generating final BAM
5
Nextera Rapid Capture Exome
(Illumina)
BWA-MEM,
version 0.7.12
Picard MarkDuplicates,
version 2.3.0
GATK PrintReads, 
version 3.7.0
6
Nextera Rapid Capture Exome
(Illumina)
BWA-MEM, 
version 0.7.10
Picard MarkDuplicates,
version 1.119
Not performed before 
generating final BAM
7
SureSelect Human All Exon V4
(Agilent Technologies)
BWA-MEM, 
version 0.7.10
Picard MarkDuplicates,
version 1.119
Not performed before 
generating final BAM
8
SureSelect Human All Exon V4
(Agilent Technologies)
BWA-MEM, 
version 0.7.10
Picard MarkDuplicates,
version 1.119
Not performed before 
generating final BAM
9
SureSelect Clinical Research Exome
(Agilent Technologies)
BWA-MEM,
version 0.7.12
Picard MarkDuplicates,
version 1.119
Not performed before 
generating final BAM
10
SureSelect Clinical Research Exome
(Agilent Technologies)
BWA-MEM, 
version 0.7.10
Picard MarkDuplicates,
version 1.119
Not performed before 
generating final BAM
11
SureSelect Clinical Research Exome V2
(Agilent Technologies)
BWA-MEM,
version 0.7.12
Picard MarkDuplicates,
version 2.3.0
GATK PrintReads, 
version 3.7.0
12
SureSelect Clinical Research Exome V2
(Agilent Technologies)
BWA-MEM,
version 0.7.12
Picard MarkDuplicates,
version 2.3.0
GATK PrintReads, 
version 3.7.0
13
SureSelect Human All Exon V6
(Agilent Technologies)
BWA-MEM,
version 0.7.12
Picard MarkDuplicates,
version 2.3.0
GATK PrintReads, 
version 3.7.0
14
SureSelect Human All Exon V6
(Agilent Technologies)
BWA-MEM,
version 0.7.12
Picard MarkDuplicates,
version 2.3.0
GATK PrintReads, 
version 3.7.0
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Quality Score Recalibration was performed before generating final BAM file, through Genome 
Analysis Toolkit software (GATK)29. As WES were performed during a period of 4 years (2014-
2018), versions of aforementioned algorithms may slightly differ (Table 3).  
First, to assess the quality and homogeneity of the WES, we evaluated the individual 
“on target” coverage, comparing each WES data with target regions of its own exome 
enrichment capture system. Next, we evaluated the coverage of miRNA “primary transcript” 
sequences, reported in miRBase v2025. The evaluation of “on target” and miRNA sequences 
experimental coverage was performed using bedtools “coverage” tool (version 2.26)85, 
without any overlapping threshold. Graphs showing relation between coverage and depth for 
target regions and miRNA sequences were generated using the R library, “ggplot2”86.  
3.1.3 Comparison with Whole Genome Sequencing data 
Since WGS experiments do not rely on a procedure for selection and capture of target 
regions, we compared data on miRNAs coverage between WES and WGS experiments. To 
this aim, we analysed two cases, specifically case 1 and 2 (Table 3), for which, besides WES 
data, we also had WGS data. We computed experimental coverage of miRNA “primary 
transcript” sequences (reported in miRBase v20)25 in WGS data, using bedtools “coverage” 
tool (version 2.26)85. To evaluate miRNAs coverage, we used WGS BAM files. Raw genome 
data were aligned to the reference genome, assembly hg19/GRCh37, using BWA-MEM 
algorithm (version 0.7.12)87 and, as WGS performed were not PCR-free, PCR duplicates were 
removed using MarkDuplicates by Picard (version 1.119)IV. We therefore compared data on 
miRNAs coverage obtained from WGS analysis with data already generated from WES 
analysis. 
As the number of WES and WGS considered was limited (2 WES and 2 WGS), we 
decided to extend our analyses on data available in the public database gnomAD (genome 
Aggregation Database version 2.0.2)36, containing 123,136 WES and 15,496 WGS.  
We therefore evaluated coverage of miRNA sequences in publicly available coverage 
data for gnomAD WES and WGS. These coverage data report, at a single nucleotide level, 
statistics on coverage, as mean and median, calculated evaluating all individuals sequenced. 
GnomAD WGS data contain coverage data for all the human genome, while gnomAD WES 
data have been processed considering only the exonic portion36. Therefore, to evaluate 
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whether gnomAD WES data have been processed in respect of miRNA sequences, we first 
assessed whether exome calling intervals contain miRNA “primary transcript” sequences, 
using bedtools “intersect” tool (version 2.26)85, with an overlapping threshold of 100%.  
Then, we analysed gnomAD WES and WGS coverage data, focusing on regions of 
miRNA “primary transcript” sequences. To select from coverage data only regions of interest, 
we used tabix (from HTSlib 1.9, SamtoolsV) and bedtools “intersect” tools (version 2.26)85. 
Next, we generated a coverage summary file for gnomAD WES and WGS data; specifically, 
we computed the same statistics provided by bedtools “coverage” tool on single BAM files, 
considering “mean” coverage values reported in gnomAD coverage data, using a R script 
(version 3.4.4)88. 
Graphs showing relation between coverage and depth for miRNA sequences in WES 
and WGS experiments were generated through the R library “ggplot2”86. 
3.2 Evaluation of microRNA variants in a cohort 
Once we assessed that WES data contain information on miRNA sequences, we 
analysed miRNA variants in a cohort composed by 259 individuals sequenced through WES 
experiments. Individuals were sequenced and analysed in a collaboration with Genetics and 
Rare Diseases Research Division at Bambino Gesù Children's Hospital, Rome, Italy. 
Specifically, in the cohort considered, 110 patients affected by several RGDs were sequenced 
to characterise molecular bases of the observed phenotypes. Where possible, relatives, 
including parents, brothers and sisters were sequenced. Therefore, the cohort of WES resulted 
composed by 110 probands (including 11 pairs of siblings) and 149 relatives (unaffected 
parents and siblings).  
WES experiments were performed in a homogeneous way: exomes were captured 
using the SureSelect Human All Exon V4 (Agilent Technologies) and were subsequently 
sequenced through the HiSeq2000 platform (Illumina). 
Raw exome data were aligned to the reference genome hg19/GRCh37 through BWA-
MEM algorithm (version 0.7.10)87. PCR duplicates were removed through MarkDuplicates by 
Picard (version 1.119)IV. Base Quality Score Recalibration was performed through GATK 
(version 3.3)29. To specifically identify germline variants localised in miRNA sequences, 
variant calling was performed through GATK Haplotype Caller (version 3.7)29 using, as calling 
regions, miRNA “primary transcript” sequences with a padding of 50bp. When multiple 
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samples of the same family were available, variant calling was performed through a joint 
calling. Hard filtering on variants was performed applying following criteria:  
1) Qual by Depth (QD) < 2.0, 
2) Fisher Strand (FS) > 60.0, 
3) Strand Odds Ratio (SOR) > 3.0, 
4) Root Mean Square of Mapping Quality (MQ) < 40.0,  
5) Mapping Quality Rank Sum Test (MQRankSum) < -12.5, 
6) Read Pos Rank Sum Test (ReadPosRankSum) < -8.0, 
7) QUAL parameter < 100.0. 
Only variants passing these criteria were identified as good quality variants and 
flagged as “PASS” or “SnpCluster” if more than 3 variants were found in a range of 10 bp.  
To analyse miRNA variants in the WES cohort, we considered only probands. When 
two patients were present in the same family, we randomly selected only one of them to 
eliminate bias due to the high amount of DNA shared between siblings. We therefore analysed 
miRNA variants on 99 probands.  
To retrieve miRNA variants, we developed a script in Python (version 2.7.14)89, that 
allowed to analyse VCF files searching for variants localising in miRNA sequences, as defined 
in miRBase v2025.  Comprehensively, the database contains the genomics coordinates of 1871 
miRNA “primary transcripts” and 2794 mature miRNAs. To better define miRNA variants 
location in miRNA sequences, we defined different miRNA regions, corresponding to the 
following substructures:  
1) Seed regions: bases from two to eight at 5’ of the mature miRNA; 
2) Mature sequences: the rest of mature miRNAs out of seed regions; 
3) Precursor regions: the regions out of mature miRNAs. 
We annotated substructures closer to 5’ end as “5p” and those closer to 3’ end as “3p”. 
When this information was not available, we calculated the distance of a miRNA substructure 
from both 5’ and 3’ end. 
MiRNAs that reside on opposite strands, but in the same genomic trait, were analysed 
separately (e.g. miR3116-1 and miR3116-2, which genomics coordinates are respectively 
chr1:62544458-62544531 and chr1:62544461-62544528). Therefore, in these cases, eventual 
variants identified were annotated in respect of substructures defined for both miRNAs.  
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To analyse only reliable variants, miRNA SNVs flagged as “PASS” with an overall 
Allel Depth (AD) equal or greater than 10 were considered.  MiRNA variants identified were 
therefore analysed considering their segregation: homozygous, heterozygous and, for 66 
probands for which we had parents, “de novo” variants. Then, variants were analysed 
considering localisation in miRNA substructures, i.e. seed, mature and precursor regions and 
their distribution was normalised on length of single substructures. 
3.2.1 Experimental validation 
Next, we selected some miRNA variants, identified in the cohort, to be experimentally 
validated. Selected miRNA variants were amplified by PCR (GoTaq Flexi DNA Polymerase – 
Promega) and analysed using Sanger sequencing (ABI BigDye Terminator Sequencing Kit 
V.3.1, ABI Prism 3500 Genetic Analyzer). Details on experimental validations performed are 
reported in Table 4.  
3.2.2 Functional annotation 
Finally, we added functional annotation regarding miRNA variants and miRNAs to 
better characterise their potential biological role. For variants, we annotated information using 
tools regarding variants frequencies (gnomAD (version 2.0.2)36 and dbSNP 15034) and their 
potential deleterious effect (CADD v 1.458 and DANN59). For miRNAs functional annotation, 
Table 4. Details on miRNA variants experimentally validated. Conditions related to PCR and Sanger 
sequencing parameters are reported along with primers used for both experiments. 
MiRNA Sequences (5'-3') PCR parameters Sequencing Reaction parameters
FW: TCATGAGTGCCAGGACTAGAC
REV: TCTCACAGGAACTCACACTCC
FW: CTGGACCACAGGTAAGACGAG
REV: ACGTCCTCCCCAGACACTTC
FW: TCATTCTGGCAGTGAACACTTC
REV: GTTGGGATCACCACCAGTTCG
FW: ATGAAGGCGAATCGCAGCCTC
REV: TCCACCCAGAACCTCTGGTC
FW: TCCTTGCCAAGCCCTTAGGTG
REV: AGTGACAACCCATTAGAAATACC
MIRLET7C
95°C - 2 min,
95°C - 30 sec/ 62°C - 30 sec / 72°C - 40 sec 30 cycles
72°C - 5 min
4°C - 5 min
96°C - 1 min,
96°C - 15 sec/ 58°C - 5 sec / 60°C - 4 min 25 cycles 
4°C - 5 min
96°C - 1 min,
96°C - 15 sec/ 58°C - 5 sec / 60°C - 4 min 25 cycles 
4°C - 5 min
96°C - 1 min,
96°C - 15 sec/ 58°C - 5 sec / 60°C - 4 min 25 cycles 
4°C - 5 min
96°C - 1 min,
96°C - 15 sec/ 58°C - 5 sec / 60°C - 4 min 25 cycles 
4°C - 5 min
MIR4634
95°C - 2 min,
95°C - 30 sec/ 62°C - 30 sec / 72°C - 40 sec 30 cycles 
72°C - 5 min
4°C - 5 min
95°C - 2 min,
95°C - 30 sec/ 62°C - 30 sec / 72°C - 40 sec 30 cycles 
72°C - 5 min
4°C - 5 min
MIR938
95°C - 2 min,
95°C - 30 sec/ 62°C - 30 sec / 72°C - 40 sec 30 cycles 
72°C - 5 min
4°C - 5 min
96°C - 1 min,
96°C - 15 sec/ 58°C - 5 sec / 60°C - 4 min 25 cycles 
4°C - 5 min
MIR146A
95°C - 2 min,
95°C - 30 sec/ 62°C - 30 sec / 72°C - 40 sec 30 cycles 
72°C - 5 min
4°C - 5 min
MIR202
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we added information relative to miRNAs associated with human diseases using data from 
HMDD v3.0 database (the Human microRNA Disease Database version 3.0)90.  
To understand how functional annotation could help in the elucidation of miRNA 
variants and miRNAs potentially related to RGDs, we first annotated miRNA variants already 
associated with Mendelian diseases and reported in Table 5. Subsequently, we annotated 
miRNA variants identified in our cohort. 
 
3.3 Development of a dedicated microRNAs analysis tool 
 To date, available systems that annotate WES data do not allow to properly analyse 
miRNA variants. We therefore decided to integrate the script used to identify miRNA 
variants, developing a dedicated tool, “AnnomiR” (“Annotation of miR”), to retrieve and 
annotate miRNA-related information from WES data. Starting from a VCF file, “AnnomiR” 
searches for variants localising in miRNAs, specifying their location, based on information 
contained in miRBase25. Furthermore, retrieving information from several databases (i.e. 
gnomAD36, dbSNP34, CADD58, DANN59 and HMDD90) downloaded locally, “AnnomiR” also 
performs functional annotation of miRNA variants and of miRNAs, annotating variants 
frequency and potential deleterious effect, and already known associations of a miRNA with 
human diseases. 
 
Table 5. MiRNA variants associated with Mendelian diseases. 
Genomic coordinate MiRNA OMIM phenotype Reference
chr7:129414596 G/T miR96 613074 Mencía et al., 2009
77
chr7:129414597 C/T miR96 613074 Mencía et al., 2009
77
chr7:129414553 A/G miR96 613074 Soldà et al., 2012
78
chr9:73424964 G/A miR204 616722 Conte et al., 2015
79
chr15:79502186 C/T miR184 614303 Hughes et al., 2011
80
; Iliff et al., 2012
81
chr15:79502137 C/A miR184 614303 Lechner et al., 2013
82
chr15:79502132 A/G miR184 614303 Lechner et al., 2013
82
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4. Results 
4.1 Whole Exome Sequencing and microRNAs: capture evaluation 
WES sequencing experiments generally produce a large amount of data that require 
both technical and biological skills to be analysed. In the study of RGDs, several assumptions 
are made to discriminate potentially pathogenetic variants among all the thousands of 
identified variants. Since 85% of disease-causative mutations in Mendelian diseases resides in 
protein coding-regions19, standard WES analyses generally focus only on protein-coding 
variants that alter coding-sequences (e.g. non-synonymous or splice sites). However, due to 
biological and technical issues, diagnostic rate of this approach is attested to be ~20-30%16,18. 
Nevertheless, WES data could contain other meaningful information that could be useful in 
the identification of the molecular bases underlying RGDs, and that is currently discarded.  
In this context, we investigated whether WES data could contain information related 
to miRNA sequences, as reported from preliminary evidences79,84. To this aim, we evaluated 
both theoretical and experimental coverage of miRNA sequences using several exome 
enrichment capture systems commercially available.  
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4.1.1 Theoretical coverage 
First, we assessed whether exome enrichment capture systems commonly used to 
perform WES experiments, contain target regions specifically designed to capture miRNA 
sequences. Among the exome enrichment capture systems analysed, three declare the 
presence of specific baits for miRNA sequences (Table 6). 
We therefore assessed whether exome kits analysed could contain probes specifically 
targeting miRNA sequences, even if not reported in technical sheets. To this aim, we 
calculated theoretical coverage of miRNAs, evaluating the overlap between target regions of 
exome enrichment capture systems considered and miRNA sequences. Results are reported 
in Figure 6 and Table 7. As it can be observed, even if in a variable quota, all exome kits 
analysed, present target regions specifically designed on miRNA sequences. 
Table 6. Exome enrichment capture systems included in this analysis. Table shows technical details 
on design of target regions.  
*This version of miRBase has been designed on hg38/GRCh38 assembly. 
Exome enrichment capture system Designed on assembly Target size (Mb) Target for miRNAs sequences
SeqCap EZ Human Exome Library v3.0
(Roche NimbleGen)
hg19/GRCh37 64
Declared in technical sheet,
designed on miRBase v16
SeqCap EZ MedExome 
(Roche NimbleGen)
hg38/GRCh38 47
Declared in technical sheet,
designed on miRBase v21*
Nextera Rapid Capture Exome
(Illumina)
hg19/GRCh37 37 Not declared
SureSelect Human All Exon V4
(Agilent Technologies)
hg19/GRCh37 51
Declared in technical sheet,
designed on miRBase v17
SureSelect Clinical Research Exome
(Agilent Technologies)
hg19/GRCh37 54 Not declared
SureSelect Clinical Research Exome V2
(Agilent Technologies)
hg19/GRCh37 67 Not declared
SureSelect Human All Exon V6
(Agilent Technologies)
hg19/GRCh37 60 Not declared
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Table 7. MiRNAs specifically targeted by exome enrichment capture systems considered. 
Exome enrichment capture system Number of miRNA specifically targeted
Nextera Rapid Capture Exome
(Illumina)
764
SeqCap EZ Human Exome Library v3.0
(Roche NimbleGen)
1154
SureSelect Human All Exon V4
(Agilent Technologies)
1383
SureSelect Clinical Research Exome
(Agilent Technologies)
1443
SureSelect Clinical Research Exome V2
(Agilent Technologies)
1634
SureSelect Human All Exon V6
(Agilent Technologies)
1634
SeqCap EZ MedExome 
(Roche NimbleGen)
1743
Figure 6. Theoretical coverage of miRNA regions in exome enrichment capture systems currently 
used. Histogram represents the theoretical coverage of miRNA “primary transcript” sequences as 
reported in miRBase v2025 among several exome kits. Coverage has been evaluated as the ratio between 
the extension of miRNA sequences overlapping with target regions and the total extension of miRNA 
sequences (both evaluated in base pairs). For complete names of exome enrichment capture systems 
considered, see Table 7. 
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4.1.2 Experimental coverage 
Next, we evaluated the effective capture of miRNA sequences from WES data. To this 
aim we analysed a representative cohort composed by 14 WES captured through 7 exome 
enrichment capture systems (2 WES for each exome kit, Table 3). 
First, we assessed the quality and homogeneity of WES data considered, calculating 
the “on target” coverage for each WES performed. Results reported in Figure 7 show the 
Figure 7. On target coverage of WES data considered. Figure reports the experimental “on target” 
coverage of each WES considered, obtained comparing each WES data with target regions of its own 
exome enrichment capture system. Values on y axis are calculated as cumulative relative frequency of 
target regions (measured in bp) effectively captured at a defined depth (reported on x axis). For 
complete names of exome enrichment capture systems considered, see Table 7. 
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uniformity of data analysed. As it can be observed, at a less stringent depth of 10X, all WES 
show a highly similar “on target” coverage, on average ~97% (ranging from 94% of SureSelect 
Clinical Research Exome V2 – Agilent Technologies to 99% of SeqCap EZ MedExome - Roche 
NimbleGen). At a more stringent depth of 20X, compatible with a highly reliable variant 
calling, “on target” coverage changes among WES data, but remains around 90% (from 86% 
obtained through SureSelect Clinical Research Exome V2 – Agilent Technologies to 98% 
reached through SeqCap EZ MedExome – Roche NimbleGen), attesting therefore the high 
quality of WES data. 
Once we assessed the homogeneity of WES data, we evaluated experimental coverage 
of miRNA sequences. Results reported in Figure 8 show the high variability observed in the 
coverage of miRNA sequences. While differences among WES captured with same exome 
enrichment capture systems are almost no detectable (curves relative to same kits are almost 
overlapped), high variability can be encountered considering the different exome enrichment 
capture systems used to perform WES experiment. Indeed, at a depth of 10X, miRNAs 
coverage is 80% on average, spanning from 52% of Nextera Rapid Capture Exome (Illumina) 
to 96% of SeqCap EZ MedExome (Roche NimbleGen). At a depth of 20X, average miRNAs 
coverage is 73%, from 46% obtained through Nextera Rapid Capture Exome (Illumina) to 91% 
reached using SeqCap EZ MedExome (Roche NimbleGen). 
Results obtained suggest that all exome enrichment capture systems considered can 
capture miRNA sequences, even if with a different efficiency. Overall, these results confirm 
that WES data contain information related to these non-coding species. 
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Figure 8. Experimental coverage of miRNA sequences. Figure reports the experimental coverage of 
miRNA sequences in each WES considered, obtained comparing each WES data with miRNA “primary 
transcript” sequences described in miRBase v2025. Values on y axis are calculated as cumulative relative 
frequency of miRNA sequences (measured in bp) effectively captured at a defined depth (reported on 
x axis). For complete names of exome enrichment capture systems considered, see Table 7. 
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4.1.2 Comparison with Whole Genome Sequencing data 
Conversely from WES, WGS experiments do not rely on capture and enrichment of 
specific target regions, allowing to sequence all coding and non-coding sequences with a 
uniform coverage. Therefore, we analysed differences in miRNA sequences coverage between 
WES and WGS, comparing data coming from these two experiments. Specifically, we 
evaluated miRNA sequences coverage in cases 1 and 2 (Table 3), for which we performed both 
WES and WGS.  
As it can be observed from Figure 9, WES and WGS present a different efficiency in 
the coverage of miRNA sequences, spanning from 68% to 98% at a depth of 10X for WES and 
WGS respectively. Differences increase if a depth of 20X is considered: while for WGS 
experiments a coverage of 93% can be observed, corresponding value for WES is 60%. Results 
obtained in the representative cohort suggest that WGS can sequence miRNA regions with a 
more uniform coverage at a greater depth compared to WES. 
Since the number of WES and WGS analysed was very limited (2 WES and 2 WGS), 
we extended the comparison to publicly available database gnomAD36, comprehending 
123,136 WES and 15,496 WGS. Coverage data publicly available for gnomAD WES data are 
available at a single nucleotide level and contain statistics on coverage measured on all 
individuals sequenced. GnomAD WGS data contain data for all genomic coordinates of the 
human genome, while gnomAD WES data contain only data relative to exonic regions as 
defined by exome calling intervals provided by gnomAD database36. 
Therefore, we first assessed whether exome calling intervals used to process gnomAD 
WES, contain miRNA sequences, evaluating the overlap between exome calling intervals and 
miRNA sequences. We found that gnomAD WES have been analysed considering all miRNA 
“primary transcript” sequences contained in miRBase v2025.   
Next, we evaluated miRNA sequences coverage for gnomAD WES and WGS. Results 
reported in Figure 10 show differences between WES and WGS: at a depth of 10X, coverage is 
53% for WES and 97% for WGS, while at a depth of 20X coverage values are respectively 48% 
and 93%. 
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These results indicate that miRNA regions are fully considered to evaluate coverage 
in gnomAD WES, and that WGS show higher and more uniform coverage of miRNA regions.  
Overall, comparison between WES and WGS confirms that WGS allow to obtain better 
results on sequencing of miRNA regions compared to WES. Nevertheless, results also confirm 
that WES contains information of miRNA sequences that is currently discarded by standard 
WES workflow of analysis.  
 
Figure 9. Experimental coverage of miRNA sequences in WES and WGS data in two cases. Figure 
reports the experimental coverage of miRNA “primary transcript” sequences (described in miRBase 
v2025 between WES and WGS experiments performed for cases 1 and 2 (Table 3). Values on y axis are 
calculated as cumulative relative frequency of miRNA sequences (measured in bp) effectively captured 
at a defined depth (reported on x axis). 
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Figure 10. Experimental coverage of miRNA sequences in WES and WGS data in a publicly available 
cohort. Figure reports the experimental coverage of miRNA “primary transcript” sequences (described 
in miRBase v2025) between WES and WGS experiments performed respectively on 123,136 WES and 
15,496 WGS contained in gnomAD36. Values on y axis are calculated as cumulative relative frequency 
of miRNA sequences (measured in bp) effectively captured at a defined depth (reported on x axis). 
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4.2 Evaluation of microRNA variants in a cohort 
Once we assessed that WES data contain miRNA-related information, we analysed 
miRNA variants in a heterogeneous cohort of 259 individuals including 110 probands (11 
pairs of siblings) and 149 unaffected relatives (parents and siblings), sequenced through WES 
experiments.  
Based on information contained in miRBase25, we developed a script to detect variants 
localising in miRNA sequences and retrieve respective information on miRNAs name and ids. 
We also annotated miRNA variants localisation, considering the substructures in 
which variants reside (as reported in Figure 11) and their distance from the 5’ and 3’ 
extremities. Therefore, miRNA variants closer to 5’ end, were annotated as “precursor-“, 
“seed-“, or “mature-“ followed by the suffix “5p”, while, for variants closer to 3’ end, suffix 
was “3p”. 
In cases in which a miRNA variant localised in two miRNAs in the same genomic 
region but on opposite strands, we annotated the single variant reporting information relative 
to both miRNAs. An example of the annotation performed is reported in Figure 12.   
To analyse only reliable variants, we selected only miRNA high quality (i.e. “PASS”) 
SNVs identified with an overall AD greater than 10.  
On 99 probands analysed, we identified 555 miRNA SNVs. Of these variants, ~70% 
(385) were found exclusively in heterozygosis, while 1% (5 variants) in homozygosis or 
hemizygosis. The remaining 165 variants were found both in heterozygosis and homozygosis. 
Figure 11. Schematic representation of miRNA substructures.  We annotated miRNA variants 
considering following substructures: seed (shown in blue), mature (in green) and precursor regions (in 
black). 
41 
 
For 66 of the 99 probands analysed we also had unaffected parents. We therefore analysed 
“de novo” variants identified in these cases, finding 49 variants. Of these variants, 7 were 
identified in two patients, therefore, overall, we found 42 “de novo” unique variants. We also 
analysed miRNA variants in respect of their localisation in miRNA substructures. We found 
71 variants in seed regions, 109 in mature regions and 375 in precursor regions; their 
distribution is reported in Figure 13. Results obtained suggest that mature and seed regions 
present a low number of miRNA variants compared to precursor regions, probably reflecting 
a different sequence conservation.  
 
 
 
 
 
Figure 12. Annotation of MiRNA variants localising in two miRNAs on opposite strands. MiRNA 
variants localising in two miRNAs on opposite strands, but in the same genomic trait, were annotated 
using information on both miRNAs. The figure shows an example for variant chr18:56118360. As it can 
be observed, variant fell in both miR-122 and miR-3591 and we therefore annotated it as seed-3p on 
miR-122 and mature-5p on miR-3591.  
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4.2.1 Experimental validation 
Among miRNA SNVs identified we selected some of them to be experimentally 
validated. Due to the high identity of sequence observed in miRNAs, we expected that some 
of them could be false positive variants. We therefore tested some of variants identified. 
Results (Figure 14) show that all selected miRNA variants were confirmed, therefore 
indicating that our detection method could be considered a reliable system to identify variants 
lying in these regions. 
 
 
 
 
 
Figure 13. Distribution of miRNA variants found in our cohort on seed, mature and precursor 
regions. Distribution has been calculated normalising miRNA variants found to length of single 
substructures. 
43 
 
4.2.2 Functional annotation 
To better characterise the potential biological role of miRNA variants, we added 
functional annotation retrieved from several databases and tools. First, we annotated data on 
variants frequencies, using gnomAD36 and dbSNP34 databases. To predict potential deleterious 
effect of identified variants, we added information from scoring systems already used for 
analysis of NGS data that can score non-coding variants, i.e. CADD58 and DANN59 systems. 
Finally, to predict potential involvement of miRNAs in human diseases, we used data 
contained in HMDD90. To test how functional annotation could help in the identification of 
miRNA variants and miRNAs potentially related to human diseases, we first annotated 
miRNA variants already associated to Mendelian diseases. Results are shown in Table 8. Five 
out of seven variants considered fell in seed regions while the other two localised in precursor 
regions, indicating that they could differently interfere with miRNA biogenesis and/or 
targeting. All variants analysed were not reported in public databases gnomAD36 and dbSNP34 
or were annotated as rare (frequency ≤ 0.01%). CADD58 and DANN59 scores were respectively 
Figure 14. Sanger validation of miRNA variants selected.  
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greater than 10 and 0.8 (used as thresholds for non-coding variants), predicting therefore a 
potential deleterious effect of miRNA variants. Finally, information retrieved from HMDD90 
report the association of miRNAs with several diseases, allowing to hypothesize the 
involvement of these miRNAs in several biological pathways, along with those already 
known. 
Overall results indicate that functional annotations allow to better characterise miRNA 
variants and miRNAs, leading to a proper investigation of their potential biological role. 
As a second step, we performed a functional annotation on miRNA variants and 
miRNAs identified in our cohort, aimed at identifying candidate miRNAs potentially 
involved in the phenotypes observed in patients sequenced. Specifically, we are considering 
variants rare or not annotated in public databases and variants predicted to be potentially 
deleterious. Furthermore, variants and miRNAs are being analysed considering their 
potential implication in human diseases, trying to correlate them with available clinical 
information on patients. 
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Table 8. MiRNA variants annotation. Table reports miRNA variants and miRNAs with their respective 
functional annotations. 
*HMDD annotations reported have been limited to human diseases already known to be associated 
with miRNAs analysed. 
ex
o
m
es
g
en
o
m
es
c
h
r7
:1
2
9
4
1
4
5
9
6
 G
/T
m
iR
9
6
M
I0
0
0
0
0
9
8
se
e
d
-5
p
.
.
.
.
2
2
.4
0
.9
4
7
9
S
e
n
so
ri
n
e
u
ra
l 
H
e
ar
in
g
 
L
o
ss
c
h
r7
:1
2
9
4
1
4
5
9
7
 C
/T
m
iR
9
6
M
I0
0
0
0
0
9
8
se
e
d
-5
p
.
.
.
.
2
2
.5
0
.9
4
8
5
S
e
n
so
ri
n
e
u
ra
l 
H
e
ar
in
g
 
L
o
ss
c
h
r7
:1
2
9
4
1
4
5
5
3
 A
/G
m
iR
9
6
M
I0
0
0
0
0
9
8
se
e
d
-3
p
rs
5
4
6
0
9
8
2
8
7
0
.0
0
2
%
0
.0
1
0
%
0
.0
0
0
2
%
2
2
.3
0
.8
5
0
8
S
e
n
so
ri
n
e
u
ra
l 
H
e
ar
in
g
 
L
o
ss
c
h
r9
:7
3
4
2
4
9
6
4
 G
/A
m
iR
2
0
4
M
I0
0
0
0
2
8
4
se
e
d
-5
p
rs
7
6
7
1
4
6
8
8
0
.
.
.
2
2
0
.9
2
2
7
C
o
lo
b
o
m
a
c
h
r1
5
:7
9
5
0
2
1
8
6
 C
/T
m
iR
1
8
4
M
I0
0
0
0
4
8
1
se
e
d
-3
p
.
.
.
.
2
2
.5
0
.9
4
9
5
C
at
ar
ac
t
c
h
r1
5
:7
9
5
0
2
1
3
7
 C
/A
m
iR
1
8
4
M
I0
0
0
0
4
8
1
p
re
c
u
rs
o
r-
5
p
rs
3
6
8
7
1
8
2
6
1
0
.0
0
7
%
0
.0
1
0
%
0
.0
0
5
%
1
4
.7
8
0
.9
4
1
4
C
at
ar
ac
t
c
h
r1
5
:7
9
5
0
2
1
3
2
 A
/G
m
iR
1
8
4
M
I0
0
0
0
4
8
1
p
re
c
u
rs
o
r-
5
p
rs
7
6
1
9
0
0
3
9
2
0
.0
0
0
4
%
.
 0
.0
0
1
%
1
4
.3
2
0
.8
3
9
2
C
at
ar
ac
t
H
M
D
D
 d
is
ea
se
s*
g
n
o
m
A
D
G
en
o
m
ic
 c
o
o
rd
in
a
te
M
iR
N
A
C
A
D
D
D
A
N
N
d
b
S
N
P
 f
re
q
u
en
cy
rs
 I
D
M
iR
N
A
 I
D
V
a
ri
a
n
t 
lo
ca
li
sa
ti
o
n
46 
 
4.3 Development of a dedicated microRNAs analysis tool 
To date, there is not a dedicated tool to properly analyse miRNA-related information 
in WES data. In this context, we integrated the script used to identify miRNA variants and 
functional annotation provided for variants and miRNAs, developing a dedicated tool, 
“AnnomiR” (“Annotation of miR”). “AnnomiR” can analyse a VCF file searching for variants 
localising in miRNAs and specifying their location in miRNA substructures. “AnnomiR” also 
annotates miRNA variants, adding information on their frequencies and their potential 
deleterious effect, retrieved from several databases (gnomAD36 and dbSNP34, and CADD58 and 
DANN59 respectively) downloaded locally. Finally, “AnnomiR” annotates miRNAs 
considering information on miRNAs already known to be associated with human diseases 
using HMDD90 database locally available.   
“AnnomiR” can be easily integrated in a workflow for WES and WGS data processing, 
allowing to analyse miRNA regions, along with coding portion of the human genome, in a 
single step analysis. 
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5. Discussion 
MicroRNAs (miRNAs) are small non-coding RNA that mediate gene silencing mostly 
recognising, by complementarity, 3’UTR of target mRNAs71,72. Expression of miRNAs is under 
tight control during development and it is subjected to a cell-specific regulation. Recently, 
miRNAs have been associated to several human diseases, comprehending both RGDs and 
complex traits70.  
Among known miRNAs dysregulation mechanisms, modifications of miRNAs 
expression profiles and sequence variants occurring in miRNAs or miRNAs-related genes 
have been disclosed. Alterations in miRNAs expression profiles can be due to several factors, 
such as changes in methylation of genes containing miRNA sequences, and responses to 
physiological and pathological stimuli, as steroid hormones or stress91. These modifications 
can significantly alter miRNAs expression, increasing or reducing miRNAs bioavailability, 
and have been so far associated with various diseases, mostly tumours91. Variants affecting 
miRNA biogenesis and function can occur in genes involved in miRNA machinery, in 3’UTR 
of target mRNAs and in miRNA sequences. Through the impairment of miRNA biogenesis 
and/or targeting, these sequence variants have been demonstrated to act both as disease-
causative and phenotypic modifiers92, in RGDs and multifactorial diseases70.  
In this context, comprehension of miRNAs alterations results crucial for the 
elucidation of molecular mechanisms that regulate onset and phenotypic variability 
underlying human diseases. Traditional methods as microarrays and quantitative reverse 
transcription PCR allow to study only expression profiles83. Information on miRNA sequences 
can be detected through Sanger sequencing and NGS approaches, such as Whole Genome 
Sequencing (WGS). 
More recently, RNA sequencing (RNA-seq) experiments allowed to study 
simultaneously both miRNA expression profiles and sequences. 
In this context, we evaluated exome enrichment capture designs and WES data of 
patients with different phenotypes in order to evaluate miRNA-related information. 
As a first step, we evaluated theoretical coverage of miRNA sequences across most 
used exome enrichment capture systems. Then, we considered the experimental coverage of 
miRNA sequences, analysing a representative cohort of 14 WES captured through 7 exome 
enrichment capture systems. Results obtained from exome enrichment kit designs and WES 
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data analyses strongly suggest that all exome kits commercially available are designed to 
target miRNA sequences and that are able to efficiently capture these regions.  
We also compared miRNAs coverage of WES with that of WGS, in 2 our cases and in 
a publicly available cohort (gnomAD database36). As expected, WGS can better sequence 
miRNA regions, showing a more uniform coverage, due to the fact that WGS experiments do 
not require a process of selection and enrichment of target regions. Data obtained from our 2 
cases, are highly concordant with data obtained from sequencing of more than 100,000 
individuals, contained in gnomAD database36. These results suggest that WES data contain 
valuable biological information that is usually non-considered using standard analysis 
workflow. Indeed, to date, no dedicated tool is available to retrieve information on miRNA 
sequences from WES and WGS experiments. 
To retrieve variants localising in miRNAs, we developed a script based on information 
contained in miRBase25. We defined specific substructures of miRNAs: seed, mature and 
precursor regions. Discriminating miRNA variants based on their location could be helpful in 
elucidating their potential biological role as variants in miRNA precursors regions can alter 
miRNA biogenesis while variants in mature and seed regions can be associated with altered 
targeting of mRNAs.  
We annotated a heterogeneous cohort of 259 WES, including patients affected by 
several genetic diseases and their unaffected relatives. The cohort represents an excellent 
system to study miRNA sequence variants as individuals were sequenced through the same 
exome enrichment capture system and sequencing platform. We specifically focused on 
probands available in this cohort, analysing 99 individuals. We identified 555 miRNA SNVs, 
retrieving information on their localisation in miRNA substructures. As already reported from 
previous studies93, results obtained show that miRNA variants are more conserved in mature 
and seed regions compared to precursor regions (Figure 13). This confirms the crucial 
functional role of these regions. However, we cannot exclude that biological and technical 
factors could influence the analysis on miRNA variants distribution. First, according also to 
previous works84,93, we are not considering a complete definition of miRNA substructures, e.g. 
loop regions, due to incomplete information available in miRBase25. Furthermore, results 
obtained are strictly related to exome enrichment capture system used to perform WES (i.e. 
SureSelect Human All Exon V4, Agilent Technologies) that include in its design ~1400 
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miRNAs (Table 7), therefore lacking ~500 miRNAs annotated in the version of miRBase used 
as reference (i.e. miRBase v2025). In addition, we cannot exclude that, besides their localisation, 
there could be other considerations to properly assess miRNA variants biological functions. 
An example could be represented by miRNAs structure conservation, that has been 
demonstrated to play a key role in regulation of miRNA biogenesis and/or function94, and that 
it is not currently considered, due to the lack of tools that allow to systematically analyse it.  
Since miRNAs are characterised by a high level of sequence identity, we evaluated 
whether called miRNA variants identified were, at least in part, false positives. Results 
obtained from experimental validations suggest instead that miRNA variants, identified 
through current calling variant algorithms (e.g. GATK29), are reliably called and, therefore, 
that these tools could be used to properly identify variants lying in these non-coding regions.  
To characterise biological information on miRNA variants and miRNAs we added 
functional annotation. With the intent to understand whether information added could be 
helpful in discriminating miRNA candidates potentially related to RGDs, we first annotated 
miRNA variants already associated with Mendelian diseases. Functional annotation added 
on miRNA variants suggest that systems currently used to analyse and prioritise coding 
variants (variants frequencies and deleteriousness scoring systems) could be powerful for 
discriminating potentially biologically relevant miRNA variants. 
The script we developed to identify miRNA variants and add functional annotation, 
“AnnomiR”, could be integrated in a standard workflow of analysis for both WES and WGS 
data. “AnnomiR” could be used to integrate analysis of data coming from patients affected by 
several human diseases, not only by RGDs, as reported in this work, but even by complex 
traits, allowing to better elucidate miRNAs role in human diseases, and giving a more 
complete overview of variability of human genome. 
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6. Conclusions 
Over the last few years, Next Generation Sequencing (NGS) technologies allowed to 
completely change the way to study Rare Genetic Diseases, accelerating the pace of discovery 
of their molecular bases. 
Currently, sequencing of the exonic portion of the human genome – the exome (1%) – 
performed through Whole Exome Sequencing (WES) experiments represents the most used 
approach to characterise molecular mechanisms underlying RGDs. However, its diagnostic 
rate is attested to be ~20-30%. To date, several tools have been developed to analyse and 
interpret data generated from WES. 
In this context, we evaluated whether WES data contain information on a non-coding 
portion of the human genome, i.e. microRNAs (miRNAs), since they have been demonstrated 
to play a key role in several human genetic diseases, acting both as disease-causative and 
phenotypic modifiers.  
The development of a dedicated tool to identify and functionally annotate miRNA 
variants and miRNAs from WES and WGS will allow to analyse these regions from NGS data. 
We expect that systematic study of miRNAs will allow to elucidate their biological role in a 
wide spectrum of human diseases, leading to a better characterisation of the variability of the 
human genome related to these non-coding sequences. 
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7. Web sites 
I. software.broadinstitute.org/gatk/best-practices/workflow?id=11145 
II. bioinformatics.babraham.ac.uk/projects/trim_galore 
III. novocraft.com/products/novoalign 
IV. broadinstitute.github.io/picard 
V. htslib.org 
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